MedTrace Logo

A Study In Adults With Moderate To Severe Dermatomyositis

NCT03181893 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-09-14

Study results available
· View outcomes & findings →

Summary

A Study looking at Investigational drug and Placebo administered to adult Patients with moderate to severe Dermatomyositis

Conditions

  • Dermatomyositis

Interventions

DRUG

PF-06823859 low

A humanized immunoglobulin neutralizing antibody

DRUG

Placebo Arm

Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid

DRUG

PF-06823859 high

A humanized immunoglobulin neutralizing antibody

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-23
Primary Completion
2022-05-27
Completion
2022-11-28
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Hungary
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03181893 on ClinicalTrials.gov